All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Suzhou Zelgen Biosciences Co. Ltd. has identified new compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
